Transplantation of allogeneic cryopreserved hematopoietic cell grafts during the Covid-19 pandemic: A National Marrow Donor Program perspective
- PMID: 33206414
- PMCID: PMC7753459
- DOI: 10.1002/ajh.26052
Transplantation of allogeneic cryopreserved hematopoietic cell grafts during the Covid-19 pandemic: A National Marrow Donor Program perspective
Comment in
-
A DKMS (German Bone Marrow Donor Center) view on cryopreservation of unrelated donor stem cell products during the Covid-19 pandemic.Am J Hematol. 2021 Mar 1;96(3):E91-E92. doi: 10.1002/ajh.26081. Epub 2021 Jan 11. Am J Hematol. 2021. PMID: 33368593 Free PMC article. No abstract available.
References
-
- Frey NV, Lazarus HM, Goldstein SC. Has allogeneic stem cell cryopreservation been given the ‘cold shoulder’? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:399‐405. - PubMed
-
- Kim DH, Jamal N, Saragosa R, et al. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transplant. 2007;13:1233‐1243. - PubMed
-
- Lioznov M, Dellbrügger C, Sputtek A, Fehse B, Kröger N, Zander AR. Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM. Bone Marrow Transplant. 2008;42:121‐128. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical